Perusing the Pipeline
With cell and gene therapies being all the rage, we take a peek at some of the advanced therapies coming down the pipe – from preclinical studies through to phase III trials.
James Strachan |
Scientists have developed a gene therapy that prevents axon destruction in mice. When an axon is damaged, either through injury or by certain therapeutic drugs, a protein called SARM1 becomes active, which triggers axons to self-destruct. This destruction likely plays an important role in multiple neurodegenerative conditions, including peripheral neuropathy, Parkinson's disease and amyotrophic lateral sclerosis. The researchers used an AAV vector to introduce point mutations into human SARM1 and inhibit its function. They found axon preservation similar to that observed in SARM1 knockout mice (1).
An international team of researchers have used gene therapy to restore hearing in an adult mouse model of DFNB9 deafness – a hearing disorder that represents one of the most frequent cases of congenital genetic deafness in humans. Individuals with DFNB9 deafness are deficient in the gene coding for otoferlin, a protein essential for transmitting sound information at auditory sensory cell synapses. The researchers used a single intracochlear injection of two different recombinant AAV vectors to reconstruct the otoferlin coding region, leading to long-term restoration of otoferlin expression in the inner hair cells, and restored hearing (2).
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!